Editorial comment: Reason for optimism

Infections in Medicine

Volumn 20, Issue 8, 2003, Pages 396-

  Diekema, Daniel J ^a   Pfaller, Michael A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DERIVATIVE; ANTIFUNGAL AGENT; FLUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDIASIS; DRUG CLASSIFICATION; EDITORIAL; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; INFECTION RISK; MORTALITY; MYCOSIS;

EID: 0041351989     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-647.
2. Gudlaugsson O, Gillespie S, Lee K, et al. Nosocomial candidemia: attributable mortality and excess length of stay revisited. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America; October 24-27, 2002; Chicago. Abstract 421.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-366.
4. Wey SB, Mori M, Pfaller MA, et al. Hospital acquired candidemia: attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642-2645.
5. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:696-709.
6. Herbrecht R, Denning DW, Patterson TF, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
7. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of ravuconazole and voriconazole compared with those of four licensed systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother. 2002;46:1723-1727.
8. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002;35:627-630.
9. Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003;47:1068-1071.
10. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-2029.